Company: ATHE
Filing Date: 2025-08-29
Form Type: 20-F
Source: 0001213900-25-082027
Chunk: 6

Company: ALTERITY THERAPEUTICS LTD
Filing Date: 2025-08-29
Form: 20-F
Item: Item 3
Chunk 6
---
 fluctuations may adversely affect the price of our securities.
------------------------------------------------------------------

●                                                                  If                                                              
    we fail to maintain compliance with NASDAQ’s continued listing requirements, our shares may be delisted from the NASDAQ Capital
                                                                Market.                                                            
-----------------------------------------------------------------------------------------------------------------------------------
Risks Related to Our Location in Australia

●                                                                      It                                                                  
    may be difficult to enforce a judgment in the United States against us and our officers and directors or to assert U.S. securities laws
                                      claims in Australia or serve process on our officers and directors.                                  
-------------------------------------------------------------------------------------------------------------------------------------------

●                                                                     As                                                                  
    a foreign private issuer whose shares are listed on the NASDAQ Capital Market, we may follow certain home country corporate governance
                                              practices instead of certain NASDAQ requirements.                                           
------------------------------------------------------------------------------------------------------------------------------------------

●                                                                    We                                                                 
    currently do not have a majority of independent directors serving on our Board of Directors, which may afford less protection to our
                            shareholders than if our Board of Directors had a majority of independent directors.                        
----------------------------------------------------------------------------------------------------------------------------------------

●                                                                   Australian                                                                
    takeovers laws may discourage takeover offers being made for us or may discourage the acquisition of large numbers of our ordinary shares.
----------------------------------------------------------------------------------------------------------------------------------------------

●                                                                    Our                                                                  
    Constitution and other Australian laws and regulations applicable to us may adversely affect our ability to take actions that could be
                                                       beneficial to our shareholders.                                                    
------------------------------------------------------------------------------------------------------------------------------------------

3

Risks Related to Our Business

We rely on research institutions to conduct our clinical trials and we may not be able to secure and maintain research institutions to conduct our future trials. The institutions that we work with have their own limits and procedures that may influence or limit our ability to conduct research and development and the conduct of clinical trials.

Our reliance upon research institutions, including public and private hospitals and clinics, provides us with less control over the timing and cost of clinical trials, clinical study management personnel and the ability to recruit subjects. If we are unable to reach agreements with suitable research institutions on acceptable terms, or if any resulting agreement is terminated, we may be unable to secure, maintain or quickly replace the research institution with another qualified institution on acceptable terms.

We are faced with uncertainties related to our research. 

Our research programs are based on scientific hypotheses and experimental approaches that may not lead to desired results. In addition, the timeframe for obtaining proof of principle and other results may be considerably longer than originally anticipated, or may not be possible given time, resource, financial, strategic and collaborator scientific constraints. Success in one stage of testing is not necessarily an indication that a